Quintrio
Home

OPHTHALMIC GOODS

The Cooper Companies, Inc. Common Stock

COO

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.

Last trade $61.05
Day change -$0.83 (-1.34%)
Day range $60.40 – $63.59
Volume 797,517
Market cap $11.77B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$11.77B
Price / earnings
20.63×
Price / book
1.41×
Price / sales
2.78×
EV / sales
3.34×
EV / EBITDA
15.25×

Profitability

Earnings per share
$3.00
Return on assets
4.5%
Return on equity
6.85%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.31×
Current ratio
1.22×
Quick ratio
0.73×
Cash ratio
0.08×

Cash flow

Price / cash flow
11.39×
Price / free cash flow
17.36×
Free cash flow
$678M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for COO, quarterly periods
Line itemQ3 FY2026 Jul 31, 2026Q2 FY2026 Apr 30, 2026Q1 FY2026 Jan 31, 2026Q4 FY2025 Oct 31, 2025Q3 FY2025 Jul 31, 2025Q2 FY2025 Apr 30, 2025Q1 FY2025 Jan 31, 2025Q4 FY2024 Oct 31, 2024
Revenue$1.07B$1.08B$1.02B$1.07B$1.06B$1B$964.7M$1.02B
Cost of revenue$354.3M$346.1M$328.9M$414.3M$368.3M$323.2M$304.5M$340.7M
Gross profit$711.9M$735.4M$695.2M$650.8M$692M$679.1M$660.2M$677.7M
Selling, general and administrative$401.3M$676.2M$390.2M$419.2M$421.7M$399M$387.9M$391.4M
Research and development$41.6M$42.5M$44.3M$41.4M$44.6M$45.5M$40.7M$37.7M
Total operating expenses$489.9M$766.4M$482.4M$510.4M$516.3M$494.3M$478.2M$479.3M
Operating income$222M-$31M$212.8M$140.4M$175.7M$184.8M$182M$198.4M
Interest expense-$21.5M-$20.9M-$22.4M-$24.4M-$25.4M-$24.2M-$26M-$27M
Income before taxes$201.8M-$48.4M$192.2M$116.8M$151.9M$144.5M$153.3M$168.6M
Income taxes-$231M$29.5M$61.4M$32.2M$53.6M$56.8M$49M$51.1M
Net income$432.8M-$77.9M$130.8M$84.6M$98.3M$87.7M$104.3M$117.5M
Net income attributable to common shareholders$432.8M-$77.9M$130.8M$84.6M$98.3M$87.7M$104.3M$117.5M
EBITDA$316.7M$64.4M$308.3M$238.8M$271.1M$277.4M$273M$289.4M
Basic earnings per share$2.24-$0.40$0.67$0.43$0.49$0.44$0.52$0.59
Diluted earnings per share$2.24-$0.40$0.66$0.43$0.49$0.44$0.52$0.59

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Lags Revenue Estimates

Marker Therapeutics reported a Q3 loss of $0.10 per share, beating EPS estimates but missing revenue expectations with $1.29 million in quarterly revenue. The company has underperformed the market by 41.6% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

GlobeNewswire Inc.

The Cooper Companies, Inc. Investor News: If You Have Suffered Losses in The Cooper Companies, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was prompted by Cooper Companies' September 10, 2026 earnings report that disappointed Wall Street with weak guidance and a decision not to sell Cooper Surgical, causing the stock to fall 14.6% that day. Investors who purchased Cooper Companies securities may be eligible for compensation through a class action lawsuit.

GlobeNewswire Inc.

The Cooper Companies, Inc. Investor News: If You Have Suffered Losses in The Cooper Companies, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was prompted by Cooper Companies' September 10, 2026 earnings report that disappointed Wall Street with weak guidance and a decision not to sell Cooper Surgical, causing the stock to fall 14.6% that day. Investors who purchased Cooper Companies securities may be eligible for compensation through a class action lawsuit.

Zacks Investment Research

Lifevantage (LFVN) Surpasses Q1 Earnings Estimates

Lifevantage reported Q3 2026 earnings of $0.05 per share, beating consensus estimates of $0.03 by 66.67%, but revenues of $37.12 million missed expectations by 3.84%. The company's year-over-year performance declined significantly with EPS down from $0.18 and revenues down from $47.56 million. The stock has underperformed the S&P 500 by 23.1% year-to-date and carries a Zacks Rank #3 (Hold) rating.

GlobeNewswire Inc.

The Cooper Companies, Inc. Investor News: If You Have Suffered Losses in The Cooper Companies, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims against The Cooper Companies, Inc. (NASDAQ: COO) for allegedly issuing materially misleading business information. The investigation was prompted by Cooper Companies' September 10, 2026 earnings report that disappointed Wall Street with weak guidance and a decision not to sell Cooper Surgical, causing the stock to fall 14.6% that day. Investors who purchased Cooper Companies securities may be eligible for compensation through a class action lawsuit.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jul 26, 2023$0.0075Aug 11, 2023recurring
Jan 20, 2023$0.0075Feb 10, 2023recurring
Jul 26, 2022$0.0075Aug 11, 2022recurring
Jan 20, 2022$0.0075Feb 9, 2022recurring
Jul 26, 2021$0.0075Aug 11, 2021recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 20, 20244-for-1forward split